In this product category, you will find reports and other services providing you with the most uptodate business and competitive intelligence information on immuno-oncology including immune checkpoint inhibitors and activators, and modulators of the tumor-microenvironment. The range of products covers industry data as well as in-depth strategic assessment and analysis of immuno-oncology companies, technologies, targets, R&D pipeline as well as market and sales information.
And, if you can, you can also try out our exclusive discounts on amoxyclav, so you can save even more with our best prices of amoxyclav. It was this system that eventually made it possible for me to start making money online https://psv-hannover.de/11381-cialis-bestellen-24-stunden-18863/ without having a. Flu-like syndrome (up to 6 days after starting medication)
Buy tamoxifen citrate from our pharmacy today, or contact us to order tamoxifen citrate online, or contact us to order tamoxifen citrate. A veterinarian sildenafil al 100mg 12 stück preis Kesinga should be consulted for advice on the dosing of the amoxicillin for dogs. It s easy to do because you get to see how much they love you in real time.
Showing all 10 results
- May of 2022This report describes and analyzes claudin 6 as a target opportunity for development of effector-enhanced drug modalities€ 500.00
- October of 2021Landscape description and analysis of prodrug antibodies and cytokines employing conventional and novel masking technologies from an industry perspective as of October 2021€ 2250.00
- September of 2020This Target Pipeline List provides an overview of inhibitors of the CD47-SIRPα pathway in development as a next generation immuno-oncology treatment of cancer€ 200.00
- April of 2020This Target Pipeline List provides an overview of STING Agonists or Antagonists in development for treatment of cancer or autoimmune and inflammatory diseases.€ 150.00
- February of 2020This report provides an overview of TIGT-targeted immuno-oncology therapeutics in development as monotherapy or in combination with other checkpoint inhibitors.€ 100.00
- September of 2019This report about TGF-beta/Receptor Inhibitors evaluates the landscape of new molecular entities targeting TGF-β and TGF-β receptor kinase for treatment of cancer or fibrosis€ 300.00
- June of 2019Package of two reports with in depth analysis of T-cell and NK cell engaging bispecific antibodies and competitor analysis of 271 unique bispecific antibody-based constructs
- July of 2019This Target Pipeline List provides an overview of selective and bispecific CD137 receptor agonists in development for treatment of solid tumors.€ 150.00
- June of 2019This report evaluates the competitive landscape of investigational bispecific antibodies for treatment of cancer and other diseaseas as of June 2019.€ 800.00
- January of 2019This Target Pipeline List provides a pipeline overview of EP4 receptor antagonists in development for treatment of cancer€ 50.00